| Literature DB >> 26556400 |
Alison Obergrussberger1, Sonja Stölzle-Feix1, Nadine Becker1, Andrea Brüggemann1, Niels Fertig1, Clemens Möller2.
Abstract
Ion channels are integral membrane proteins that regulate the flux of ions across the cell membrane. They are involved in nearly all physiological processes, and malfunction of ion channels has been linked to many diseases. Until recently, high-throughput screening of ion channels was limited to indirect, e.g. fluorescence-based, readout technologies. In the past years, direct label-free biophysical readout technologies by means of electrophysiology have been developed. Planar patch-clamp electrophysiology provides a direct functional label-free readout of ion channel function in medium to high throughput. Further electrophysiology features, including temperature control and higher-throughput instruments, are continually being developed. Electrophysiological screening in a 384-well format has recently become possible. Advances in chip and microfluidic design, as well as in cell preparation and handling, have allowed challenging cell types to be studied by automated patch clamp. Assays measuring action potentials in stem cell-derived cardiomyocytes, relevant for cardiac safety screening, and neuronal cells, as well as a large number of different ion channels, including fast ligand-gated ion channels, have successfully been established by automated patch clamp. Impedance and multi-electrode array measurements are particularly suitable for studying cardiomyocytes and neuronal cells within their physiological network, and to address more complex physiological questions. This article discusses recent advances in electrophysiological technologies available for screening ion channel function and regulation.Entities:
Keywords: Automated patch clamp; Electrophysiology; action potential; cardiomyocytes; impedance; ion channels; safety pharmacology; screening; temperature
Mesh:
Substances:
Year: 2015 PMID: 26556400 PMCID: PMC4850050 DOI: 10.1080/19336950.2015.1079675
Source DB: PubMed Journal: Channels (Austin) ISSN: 1933-6950 Impact factor: 2.581
Figure 1.For figure legend, see next page.Figure 1 (See previous page). (A) Schematic of conventional patch clamp set-up showing the patch clamp pipette attached to the cell membrane. The cell is attached to the bottom of the dish and is viewed using a microscope. A ground electrode is positioned in the external solution and the internal electrode in the patch clamp pipette is attached to the amplifier headstage. Reproduced with permission from Brüggemann et al.42 © Wiley. Reproduced by permission of Bettina Loycke. Permission to reuse must be obtained from the rightsholder. (B) Schematic of a planar patch clamp set-up as used for the Port-a-Patch, Patchliner, SyncroPatch 96 and SyncroPatch 384PE. Here the cell is attached to the glass of the patch clamp chip. A ground electrode is positioned in the external solution and the internal electrode at the bottom of the planar chip is attached to the amplifier headstage. Reproduced with permission from Brüggemann et al.42 © Wiley. Reproduced by permission of Bettina Loycke. Permission to reuse must be obtained from the rightsholder. (C) The Patchliner chip. The planar glass layer which contains the patch clamp aperture is sandwiched between 2 plastic molds creating micro-fluidic channels. The pipette of the Patchliner is shown positioned in the channel for delivering external solution, cells and compounds. (D) Schematic of the Patchliner chip. The cell is shown positioned on the patch clamp aperture in the whole cell configuration. When solutions are added on the external side, the existing solution is pushed into the waste chamber and the external solution is completely exchanged. The waste chamber is emptied continuously using an external waste pump. (E) The Patchliner was used to repetitively activate nAChα7R expressed in HEK cells by nicotine on the Patchliner. The solutions were stacked inside the pipette of the Patchliner to minimise exposure time. Shown are 8 consecutive applications of 100 µM nicotine. Peak amplitude is consistent over all 8 applications. Inset shows nAChα7R activation of the first application expanded. Reproduced with permission from Obergrussberger et al.17 © Wiley. Reproduced by permission of Paulette Goldweb. Permission to reuse must be obtained from the rightsholder. (F) Current traces of TRPV3 expressed in HEK cells when activated by heated solution. External solution was heated inside the pipette of the Patchliner to the temperature shown and applied to the cell. Currents started to activate at ≥ 38°C. (Reproduced with permission from Stoelzle et al.14 © Sonja Stoelzle-Feix, reproduced by permission of Sonja Stoelzle-Feix. Permission to reuse must be obtained from the rightsholder.
Comparison of automated patch clamp devices available on the market. Information contained within the table was collected from relevant company websites: www.nanion.de; www.moleculardevices.com; www.sophion.com and www.fluxionbio.com. * 16 amplifier channels and a multiplexer are used. ** 10 ms for Fast Perfusion Kit for the Port-a-Patch and 100 ms for standard External Perfusion System. *** rough estimates from the manufacturers and vendors, depending on cells, protocols etc.
| Instrument | Port-a-Patch | Patchliner | PatchXpress | QPatch | SyncroPatch 96 | IonFlux | Qube | IonWorks Barracuda | SyncroPatch 384PE |
|---|---|---|---|---|---|---|---|---|---|
| Company | Nanion | Nanion | MDS | Biolin Scientific (Sophion) | Nanion | Fluxion | Biolin Scientific (Sophion) | MDS | Nanion |
| Recording substrate | Glass, single hole or multiple holes per well | Glass, single hole or multiple holes per well | Glass, single hole per well | Silicon, single hole or multiple holes per well | Glass, single hole or multiple holes per well | PDMS, Single hole or 20 holes per well | Polymer, single hole or 10 holes per well | Polymer, single hole or population patch with 64 holes per well | Glass, single hole or multiple holes per well |
| Recording configurations | Whole cell, cell attached, perforated patch, bilayer recordings. | Whole cell, cell attached, perforated patch, bilayer recordings | Whole cell | Whole cell | Whole cell, perforated patch | Whole cell | Whole cell | Perforated patch (loose patch) | Whole cell, perforated patch |
| No. parallel recordings | 1 | 4 or 8 | 16 | 8, 16 or 48 | 96* | 16 or 64 | 384 | 384 | 384/768 |
| Throughput*** | 50 data points/day | 250-500 data points/day | 500 compounds per 8 hour day | 250–3000 data points/day | 6000 data points/day | 2500–8000 data points/day | 30,000 compounds per 24 hours | 1100 - 6000 data points/hour | 20,000–38,000 data points/ day |
| Seal resistance | GΩ | GΩ | GΩ | GΩ | GΩ | GΩ | GΩ | 50–100 MΩ | GΩ |
| Compatible cells | Cell lines, primary cells, stem cells | Cell lines, primary cells, stem cells | Cell lines, stem cells | Cell lines, stem cells | Cell lines, stem cells | Cell lines, primary cells | Cell lines | Cell lines | Cell lines, stem cells |
| Temperature control | Optional | Optional | No | Optional | No | Yes (up to 40°C) | Not known | No | Optional |
| Current clamp | Yes | Yes | Yes | Yes | No | No | Not known | No | Yes |
| Number of pipettes | N/A | 1 | 16 | 2, 4 or 8 | 16 | N/A | 384 | 384 | 384 |
| External solution exchange time | 10 - 100 ms** | 10 ms | 10–15 ms | 10 ms | 100 ms | 100 ms | Not known | 40 ms (single hole per well) to 80 ms (Population patch) | 50 ms |
| Internal solution exchange | Yes | Yes | No | No | Yes | No | No | No | Yes |
Figure 2.(A) Current-voltage plot of an average of 4 iPS cardiac cells (Cellectis) recorded on one run of the Patchliner. The currents were normalized to the maximum peak amplitude. The inset shows raw traces from an exemplar cell in response to voltage steps from −80 mV to 40 mV. Currents started to activate about −50 mV and peak response was elicited at around −20 mV. Bi Current responses of an iPS cardiac cell to a voltage protocol to −20 mV from a holding potential of −120 mV in control conditions and in the presence of 100 µM tetracaine. Tetracaine almost completely blocked the current response at this concentration, an effect that was completely reversible upon washout (trace not shown). Bii Action potentials were elicited in the current clamp mode using a 1 ms depolarizing current pulse. A holding current of −185 pA was used to maintain a baseline voltage of −96 mV. The action potential in control conditions is shown in black. The sodium channel blocker, tetracaine, at 100 µM was applied and this inhibited the action potentials (blue). The effect could be reversed upon washout (gray). (C) Current-voltage relationship of an average of 54 iPS neurons (CDI) recorded on the Patchliner. The inset shows raw traces from an exemplary cell showing NaV and KV currents present in the cell. Fast, transient inward Nav currents started to activate at about −40 mV, and peak currents were elicited at −10 mV or −20 mV. (D) Activation of currents in iPS neurons (CDI) by the ligand GABA (30 µM). GABA was applied for approximately 600 ms before washout with external solution using a stacked solutions approach. Cells were held at a constant holding potential of −70 mV. (E) Action potential elicited from an iPS neuron (CDI) recorded on the Patchliner. Action potentials were elicited using a 2ms depolarizing pulse. Panels (C-E) reproduced with permission from Haythornthwaite et al.28 © SAGE. Reproduced by permission of Michelle Binur. Permission to reuse must be obtained from the rightsholder.
Figure 3.Screenshot of PatchControl 384, the software for the SyncroPatch 384PE, during a recording of 6 cardiac ion channels expressed in different cell lines. Four columns of the patch clamp chip (64 wells) received one cell line expressing either hERG (HEK), KV4.3 (CHO), KV7.1 (CHO), Kir2.1 (HEK), NaV1.5 (CHO) or CaV1.2 (CHO). All cell lines were provided by ChanTest (a Charles River Company). A voltage protocol was designed to activate all channels simultaneously, shown at the top of the figure. The first step to 0 mV (1) was used to activate NaV1.5 and CaV1.2, the second part of the protocol to 60 mV followed by a step to −40 mV (2) was used to activate KV4.3, hERG and KV7.1 and the final ramp (3) was used to activate Kir2.1. The columns are scaled individually to expand the relevant current and an example is shown at the top of each set of columns.
Figure 4.(A) Schematic setup of impedance measurement electrodes in the CardioExcyte 96 (Nanion Technologies). (B) The CE96 is capable of performing impedance and EFP recordings in combination. Top trace shows an EFP recording which represents the electrophysiological activity, the bottom trace shows the corresponding impedance trace which represents the contractility of the beating network. Note that the spikes in the beginning of the EFP trace are due to the fact that one recording electrode is used with which the electrical activity of the complete cardiomyocyte network is detected, translocation of the signal thus results in slightly shifted Na spikes. (C) 96-well view of an exemplary experimental layout in the impedance mode. Different concentrations of compounds were tested on Cor.4U cardiomyocytes (Axiogenesis). The compound-induced effects on the beat rate, amplitude or beat irregularity (arrhythmia), among other parameters, can be viewed online during the experiment. Panels (A and C) reproduced with permission from Doerr et al.32 © SAGE. Reproduced by permission of Michelle Binur. Permission to reuse must be obtained from the rightsholder.